ReviewHead and neck pathology2025
Ghost Cell Odontogenic Carcinoma: Case Series and Literature Review.
Review in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ghost cell odontogenic carcinoma (GCOC) is rare. These tumors can arise from odontogenic precursors or de novo, displaying a spectrum of clinical behaviors with potential for rapid local recurrence, distant metastasis, and death from disease. Considering limited data, we present two cases of GCOC in female patients and perform a comprehensive review of the literature related to GCOC with a focus on adjuvant therapies. The first case, a de novo occurrence, had an aggressive course, while the second, arising from an ameloblastoma, was more indolent. A review of 65 previously published cases revealed that 82% of GCOCs occurred in males. Recurrence rates were higher in cases arising from precursor lesions (64%) compared with de novo lesions (26%). Of the 59 patients who had documented follow-up, 37% had an isolated local recurrence, 3% had an isolated distant metastasis, and 5% had both a local recurrence and distant metastasis. Overall, GCOC is a rare but aggressive odontogenic carcinoma requiring a multidisciplinary approach. Radical surgical excision with clear margins remains the primary treatment. Adjuvant therapies, such as radiotherapy, are indicated for aggressive features like rapid growth, positive margins, and local recurrence. While both local and distant recurrences are a risk, local recurrence is the most common mode of treatment failure. Further research into prognostic markers such as CTNNB1, p53, and Ki-67 may lead to more personalized therapies and improved outcomes. Additional research should also focus on intensifying adjuvant therapies to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.